A Study to Evaluate the Safety and Efficacy of Relugolix in Men With Advanced Prostate Cancer
Status:
Active, not recruiting
Trial end date:
2021-11-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the efficacy and safety of relugolix 120 milligrams
(mg) orally once daily for 48 weeks on maintaining serum testosterone suppression to castrate
levels (< 50 nanograms/deciliter [ng/dL]) in participants with androgen-sensitive advanced
prostate cancer.